C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Pipeline Review, H1 2016', provides in depth analysis on C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted pipeline therapeutics. 

The report provides comprehensive information on the C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4)
- The report reviews C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) Overview 6
Therapeutics Development 7
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Products under Development by Stage of Development 7
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Products under Development by Therapy Area 8
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Products under Development by Indication 9
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Products under Development by Companies 12
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development 20
AstraZeneca Plc 20
ChemoCentryx, Inc. 21
Globavir Biosciences, Inc. 22
Kyowa Hakko Kirin Co., Ltd. 23
Ono Pharmaceutical Co., Ltd. 24
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Drug Profiles 25
AZD-2098 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CCX-6239 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
E-0001163 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
GBV-3019 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
K-777 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
mogamulizumab - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Dormant Projects 35
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Discontinued Products 36
C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Featured News & Press Releases 37
Jul 29, 2015: Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S. 37
Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab 37
Dec 10, 2014: Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab in Advanced Solid Tumors 38
Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study 38
Jun 30, 2014: Reapplication Seeking Approval for Additional Indication for ATL of Mogamulizumab 39
Mar 17, 2014: Approval for Additional Indication for PTCL and CTCL of Mogamulizumab 39
Feb 10, 2014: Change to Supplemental Application Seeking Approval of Additional Indication for Mogamulizumab 40
Jan 15, 2014: Addition of Japanese Sites for Pivotal Phase 3 Trial of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma 40
Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 41
Dec 13, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase III Trial Of Mogamulizumab In Patients With Cutaneous T-Cell Lymphoma In US 41
Dec 11, 2012: Kyowa Hakko Kirin Announces Presentation Of Phase II Clinical Trial Results Of Mogamulizumab At ASH Annual Meeting 42
Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe 42
Jul 19, 2012: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 43
May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan 43
Mar 30, 2012: Kyowa Hakko Kirin Receives New Drug Application Approval For POTELIGEO Injection 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 15
Number of Products by Stage and Route of Administration, H1 2016 17
Number of Products by Stage and Molecule Type, H1 2016 19
Pipeline by AstraZeneca Plc, H1 2016 20
Pipeline by ChemoCentryx, Inc., H1 2016 21
Pipeline by Globavir Biosciences, Inc., H1 2016 22
Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 23
Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 24
Dormant Projects, H1 2016 35
Discontinued Products, H1 2016 36